OBJECTIVE:Pregabalin (PGB) is an α2 δ calcium-channel subunit ligand that has previously been shown to reduce chronic pain in multiple conditions. Preclinical studies indicate that PGB may down-regulate brain glutamate release while also inhibiting astrocyte induction of glutamatergic synapse formation, and recent clinical findings support the notion that PGB modulates glutamatergic activity and functional brain connectivity in order to produce analgesia. The present study was undertaken to examine concurrent changes in brain gray matter volume (GMV) or evoked-pain connectivity in humans receiving PGB. METHODS:Sixteen female fibromyalgia patients participated in a randomized double-blind 2-period crossover study of PGB versus placebo. Before and after each period, patients underwent high-resolution structural and evoked pressure-pain functional brain imaging. GMV was analyzed using voxel-based morphometry, and functional connectivity during evoked pressure-pain was assessed. RESULTS:PGB administration significantly reduced GMV within the posterior insula bilaterally, whereas there were no significant changes in insular GMV following placebo treatment. GMV reductions in the medial frontal gyrus were also observed when comparing PGB versus placebo treatment, and were associated with reduced clinical pain. These reductions in insular GMV were associated with concomitant reductions in connectivity to the default mode network, which was also associated with reduced clinical pain. CONCLUSION: Short-term PGB treatment altered brain structure and evoked-pain connectivity, and these decreases were associated with reduced clinical pain. We speculate that these fairly rapid changes in GMV may be related to brain neuroplasticity. It is unknown whether these effects are generalizable to other chronic pain states.
RCT Entities:
OBJECTIVE:Pregabalin (PGB) is an α2 δ calcium-channel subunit ligand that has previously been shown to reduce chronic pain in multiple conditions. Preclinical studies indicate that PGB may down-regulate brain glutamate release while also inhibiting astrocyte induction of glutamatergic synapse formation, and recent clinical findings support the notion that PGB modulates glutamatergic activity and functional brain connectivity in order to produce analgesia. The present study was undertaken to examine concurrent changes in brain gray matter volume (GMV) or evoked-pain connectivity in humans receiving PGB. METHODS: Sixteen female fibromyalgiapatients participated in a randomized double-blind 2-period crossover study of PGB versus placebo. Before and after each period, patients underwent high-resolution structural and evoked pressure-pain functional brain imaging. GMV was analyzed using voxel-based morphometry, and functional connectivity during evoked pressure-pain was assessed. RESULTS:PGB administration significantly reduced GMV within the posterior insula bilaterally, whereas there were no significant changes in insular GMV following placebo treatment. GMV reductions in the medial frontal gyrus were also observed when comparing PGB versus placebo treatment, and were associated with reduced clinical pain. These reductions in insular GMV were associated with concomitant reductions in connectivity to the default mode network, which was also associated with reduced clinical pain. CONCLUSION: Short-term PGB treatment altered brain structure and evoked-pain connectivity, and these decreases were associated with reduced clinical pain. We speculate that these fairly rapid changes in GMV may be related to brain neuroplasticity. It is unknown whether these effects are generalizable to other chronic pain states.
Authors: Angela R Laird; Simon B Eickhoff; Karl Li; Donald A Robin; David C Glahn; Peter T Fox Journal: J Neurosci Date: 2009-11-18 Impact factor: 6.167
Authors: Richard E Harris; Vitaly Napadow; John P Huggins; Lynne Pauer; Jieun Kim; Johnson Hampson; Pia C Sundgren; Bradley Foerster; Myria Petrou; Tobias Schmidt-Wilcke; Daniel J Clauw Journal: Anesthesiology Date: 2013-12 Impact factor: 7.892
Authors: Aaron Kucyi; Massieh Moayedi; Irit Weissman-Fogel; Michael B Goldberg; Bruce V Freeman; Howard C Tenenbaum; Karen D Davis Journal: J Neurosci Date: 2014-03-12 Impact factor: 6.167
Authors: Sylvia M Gustin; Jamie G McKay; Esben T Petersen; Chris C Peck; Greg M Murray; Luke A Henderson Journal: PLoS One Date: 2014-10-07 Impact factor: 3.240
Authors: Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky Journal: Blood Adv Date: 2019-12-10
Authors: Chelsea M Kaplan; Andrew Schrepf; Deniz Vatansever; Tony E Larkin; Ishtiaq Mawla; Eric Ichesco; Laura Kochlefl; Steven E Harte; Daniel J Clauw; George A Mashour; Richard E Harris Journal: Pain Date: 2019-04 Impact factor: 7.926
Authors: Anna Woodbury; Lisa C Krishnamurthy; Anastasia Bohsali; Venkatagiri Krishnamurthy; Jeremy L Smith; Melat Gebre; Kari Tyler; Mark Vernon; Bruce Crosson; Jerry P Kalangara; Vitaly Napadow; Jason W Allen; Daniel Harper Journal: Neurobiol Pain Date: 2022-05-17
Authors: David Borsook; Andrew M Youssef; Nadia Barakat; Christine B Sieberg; Igor Elman Journal: Neurosci Biobehav Rev Date: 2018-02-21 Impact factor: 8.989